Compare HCA Health Inc (HCA) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Ryanair Holdings plc — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while Ryanair Holdings plc trades at $54.24 (market cap $27.11B). The key difference: HCA Health Inc is far larger — about 3.6× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Ryanair Holdings plc for 72 Days on average.
| HCA | RYAAY | |
|---|---|---|
Market Cap | $96.35B | $27.11B |
Volume | 1,079,453 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $545.13 | $73.82 |
52-Week Low | $361.32 | $51.95 |
Typical Hold Time | 76 Days | 72 Days |
Enterprise Value | $146.88B | $24.18B |
Dividend Yield | 0.7% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $445.01, up 1.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.60 billion in 2025, with a net income margin of 8.77%. The stock is supported by a consensus analyst price target of $461.12 and a 63% buy rating. Recent news includes an upcoming Q3 2026 earnings call and completion of the College of Health Care Professions acquisition, highlighting growth initiatives amid ongoing legal investigations.
Outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and regulatory scrutiny. The stock offers value with a P/E of 14.92 and upside to the price target, though high debt levels and legal overhangs warrant caution for investors seeking stable healthcare exposure.
RYAAY trades at $54.04, down 3.5% today, with technical indicators showing bearish momentum. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at P/E 13.43. Recent earnings show mixed results with Q1 beat but Q2 miss. Analyst consensus remains positive with 65% buy ratings despite near-term headwinds from fuel costs and Boeing MAX 10 certification delays.
RYAAY presents a value opportunity with solid profitability and growth prospects, though investors face near-term risks from volatile fuel prices and operational challenges. The airline's low-cost leadership and market share gains support long-term upside, but winter capacity cuts and unhedged oil exposure require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
